Hansa Biopharma update: The European launch regains momentum - Redeye

With the increased number of active centers, the complete enrolment of the European PAES study, and the record level of IDEFIRIX product sales is a welcome positive surprise. We continue to expect quarterly variations, which are now at a higher level and along a more positive, robust trend. We strongly welcome Renee Aguiar-Lucander as the new CEO, and the main near-term challenge is to secure growth capital.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099659/hansa-biopharma-update-the-european-launch-regains-momentum?utm_source=finwire&utm_medium=RSS